Seres therapeutics to host investor webcast on december 8, 2022 to discuss ser-109 commercial strategy

Cambridge, mass.--( business wire )--seres therapeutics, inc. (nasdaq: mcrb), a leading microbiome therapeutics company, today announced that it will host an investor webcast to discuss the planned commercialization approach and market opportunity for therapeutic candidate ser-109 in recurrent c. difficile infection (rcdi) on thursday, december 8, 2022, at 8:30 a.m. et and is expected to be approximately one hour in duration.
MCRB Ratings Summary
MCRB Quant Ranking